Epithelial-mesenchymal transition in colorectal cancer tissue of patients with Lynch syndrome

Table 1 Clinical data of patients

Group	n	Male	Female	Age (χ2± SD, yr)	Lesions		Dukes stage
					Colon	Rectum	A	B	C	D
Lynch syndrome	30	23	7	18-68 (46.0 ± 10.6)1	21	9	2	19	7	2
Sporadic CRC	30	20	10	60-89 (70.3 ± 7.2)2	19	11	1	11	15	3
Adjacent tissues	8	6	2	45-70 (57.8 ± 8.1)3	6	2

¹Lynch syndrome vs sporadic CRC (u = -6.637, P = 0.000);

²Sporadic CRC vs adjacent tissues (u = -3.447, P = 0.000);

³Lynch syndrome vs adjacent tissues (u = -2.238, P = 0.026). CRC: Colorectal carcinoma.

Table 2 The expression of hMSH2, hMLH1, TGFβRII, E-cadherin, β-catenin, matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-2 in three groups

Group	n	hMSH2			hMLH1			TGFβRII			E-cadherin		Cytomembraneβ-catenin		Cytoplasmicβ-catenin		MMP-7			TIMP-2
		-	+	++	-	+	++	-	+	++	-	+	-	+	-	+	-	+	++	-	+	++
Lynch syndrome	30	23a	7	0	14a	9	7	18a	8	4	4	26a	5	25a	16a	14	16a	11	3	11	15a	4
Sporadic CRC	30	11c	19	0	5c	11	14	8c	14	8	12c	18	15c	15	6	24c	4	16	10c	24	6	0
Adjacent tissues	8	0	1	7e	0	0	8e	0	1	7e	0	8	0	8	8e	0	8e	0	0	8e	0	0

^aLynch syndrome vs sporadic CRC;

^cSporadic CRC vs adjacent tissues;

^eLynch syndrome vs adjacent tissues, P < 0.05. CRC: Colorectal carcinoma.

Table 3 The relation of expression of hMSH2, hMLH1, TβRII, E-cadherin, β-catenin, matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-2 with clinicopathological characteristics of Lynch syndrome and sporadic colorectal carcinoma

Clinicopathological parameter	n	hMSH2	hMLH1	TGFβRII	E-cadherin	Cytomembraneβ-catenin	Cytoplasmicβ-catenin	MMP-7	TIMP-2
Lynch syndrome	30	7	16	12	26	25	14	14	19
Male	23	4	10	10	21	20	9	12	14
Female	7	3	6	2	5	5	5	2	5
Tumor size
< 4 cm	16	4	8	7	14	13	8	8	10
≥ 4 cm	14	3	8	5	12	12	6	6	9
Position
Right half of colon	18	4	9	7	16	16	9	10	11
Left half of colon	3	1	2	1	3	2	1	1	2
Rectum	9	1	5	4	7	7	4	3	6
Invasion
Inner chorion	21	5	10	11a	21a	20a	7	7	17ac
Outer chorion	9	2	6	1	5	5	7a	7a	2c
Metastasis
No	21	4	11	11a	21a	20a	7	6	18ac
Yes	9	3	5	1	5	5	7a	8a	1
Sporadic CRC	30	19	25	22	18	15	24	26	6
Male	20	12c	17c	14	11	10	17	18	4
Female	10	7	8	8	7	5	7	8	2
Tumor size
< 4 cm	13	9c	11c	9	8	7	11	10	4
≥ 4 cm	17	10c	14	13	10	8	13	16	2
Position
Right half of colon	14	8c	11	12	9	9	12	13	3
Left half of colon	5	4	4	3	3	2	3	4	1
Rectum	11	7c	10	7	6	4	9	9	2
Invasion
Inner chorion	14	7	11	13ac	12a	10a	9	10c	5a
Outer chorion	16	12c	14	9b	6	5	15a	16a	1
Metastasis
No	12	7c	10	12ac	10a	9a	7	8c	5a
Yes	18	12	15	10c	8	6	17a	18a	1

^aCompared within the group;

^cCompared between groups, P < 0.05. CRC: Colorectal carcinoma; TGFβRII: Transforming growth factor-β type II receptor; MMP-7: Matrix metalloproteinase-7.

Table 4 The correlation of hMSH2, hMLH1, TGFβRII, E-cadherin, β-catenin, matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-2 expression in Lynch syndrome

Lynch syndrome		hMSH2			hMLH1			TGFβRII			E-cadherin		Cytomembraneβ-catenin		Cytoplasmicβ-catenin		MMP-7
		(++)	(+)	(-)	(++)	(+)	(-)	(++)	(+)	(-)	(+)	(-)	(+)	(-)	(+)	(-)	(++)	(+)	(-)
hMLH1	(++)	0	7	0
	(+)	0	0	9
	(-)	0	0	14
TGFβRII	(++)	0	2	2	0	0	4
	(+)	0	4	4	0	0	8
	(-)	0	1	17	7	9	2
E-cadherin	(+)	0	7	19	6	7	13	3	7	16
	(-)	0	0	4	1	2	1	1	1	2
Cytomembrane β-catenin	(+)	0	5	20	4	8	13	3	6	16	21	4
	(-)	0	2	3	3	1	1	1	2	2	5	0
Cytoplasmic β-catenin	(+)	0	3	11	2	6	6	1	2	11	14	0	10	4
	(-)	0	4	12	5	3	8	3	6	7	12	4	15	1
MMP-7	(++)	0	2	1	2	0	1	1	2	0	1	2	1	2	2	1
	(+)	0	4	7	4	1	6	3	2	6	10	1	9	2	9	2
	(-)	0	1	15	1	8	7	0	4	12	15	1	15	1	3	13
TIMP-2	(++)	0	2	2	2	1	1	0	0	4	3	1	3	1	2	2	1	1	2
	(+)	0	2	13	2	8	5	0	4	11	13	2	13	2	8	7	1	6	8
	(-)	0	3	8	3	0	8	4	4	3	10	1	9	2	4	7	1	4	6

Table 5 The correlation of hMSH2, hMLH1, TGFβRII, E-cadherin, β-catenin, matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-2 expression in sporadic colorectal carcinoma

Sporadic CRC		hMSH2			hMLH1			TGFβRII			E-cadherin		Cytomembraneβ-catenin		Cytoplasmicβ-catenin		MMP-7
		(++)	(+)	(-)	(++)	(+)	(-)	(++)	(+)	(-)	(+)	(-)	(+)	(-)	(+)	(-)	(++)	(+)	(-)
hMLH1	(++)	0	14	0
	(+)	0	5	6
	(-)	0	0	5
TGFβRII	(++)	0	4	4	7	0	1
	(+)	0	10	4	7	5	2
	(-)	0	5	3	0	6	2
E-cadherin	(+)	0	12	6	12	4	2	6	9	3
	(-)	0	7	5	2	7	3	2	5	5
Cytomembrane β-catenin	(+)	0	13	2	9	5	1	6	8	1	12	3
	(-)	0	6	9	5	6	4	2	6	7	6	9
Cytoplasmic β-catenin	(+)	0	14	10	13	8	3	7	11	6	15	9	10	14
	(-)	0	5	1	1	3	2	1	3	2	3	3	5	1
MMP-7	(++)	0	6	4	6	2	2	7	3	0	8	2	5	5	7	3
	(+)	0	12	4	6	9	1	1	11	4	10	6	10	6	14	2
	(-)	0	1	3	2	0	2	0	0	4	0	4	0	4	3	1
TIMP-2	(++)	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	(+)	0	4	2	4	0	2	2	2	2	5	1	4	2	1	5	4	2	0
	(-)	0	15	9	10	11	3	6	12	6	13	11	11	13	23	1	6	14	4